SWITCHING OUT OF CLASS OR TO ANOTHER ANTI-TNF AGENT IS THE BEST STRATEGY FOR CLINICAL EFFICACY AND TREATMENT PERSISTENCE IN IBD PATIENTS WITH ANTI-DRUG ANTIBODIES AGAINST ANTI-TNF

被引：0
|
作者：
Anjie, Suzanne I.
Hanzel, Jurij
Gecse, Krisztina B.
D'Haens, Geert
Brandse, Johannan F.
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1774
引用
收藏
页码：S1120 / S1121
页数：2
相关论文
共 50 条
  • [21] Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease
    Ha, Christina
    Mathur, Jagrati
    Kornbluth, Asher
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 9 (04) : 497 - 505
  • [22] The kinetics of anti-drug antibody formation against anti-TNF biological adalimumab
    Valk, Anika Marilou
    Van Strien, Jolinde
    Loeff, Floris C.
    Dijk, Lisanne
    Wolbrink, Gertjan
    Ten Brinke, Anja
    Rispens, Theo
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 : 227 - 227
  • [23] Relevance of anti-drug antibodies in context of supra-therapeutic anti-TNF concentrations
    Kim, J.
    Walshe, M.
    Borowski, K.
    Milgrom, R.
    Stempak, J.
    Lee, S. H.
    Croitoru, K.
    Silverberg, M. S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I933 - I934
  • [24] Outcomes in IBD Patients Who Are Exposed to a Subsequent Anti-TNF Agent Following Anti-TNF Drug Induced Lupus-Like Reaction
    Venu, Mukund
    Dodda, Amar
    Gonzaga, Jason E.
    Naik, Amar S.
    Venu, Nanda
    Perera, Lilani P.
    Stein, Daniel
    GASTROENTEROLOGY, 2013, 144 (05) : S409 - S409
  • [25] FACTORS ASSOCIATED WITH SWITCHING FROM ONE ANTI-TNF AGENT TO ANOTHER ANTI-TNF, OR IL17 AGENT IN PATIENT WITH ANKYLOSING SPONDYLITIS
    Hwang, M.
    Weisman, M.
    Gensler, L. S.
    Tahanan, A.
    Ishimori, M.
    Hunter, T.
    Bolce, R.
    Lisse, J.
    Rahbar, M.
    Shan, M.
    Reveille, J. D.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 710 - 710
  • [26] Antibodies to anti-TNF therapy—consequences for IBD management
    Welmoed K. van Deen
    Daniel W. Hommes
    Nature Reviews Gastroenterology & Hepatology, 2013, 10 : 446 - 448
  • [27] Measurement of Anti-TNF Agents and Anti-Drug Antibodies Serum Levels in Patients with Inflammatory Bowel Disease
    Guerra, Ivan
    Chaparro, Maria
    Bermejo, Fernando
    Gisbert, Javier P.
    CURRENT DRUG METABOLISM, 2014, 15 (09) : 875 - 881
  • [28] Is anti-TNF therapeutic drug monitoring of value in IBD patients in clinical remission?
    Subramaniam, K.
    Watthayalage, R.
    Neeman, T.
    Pavli, P.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 149 - 149
  • [29] Is anti-TNF therapeutic drug monitoring of value in IBD patients in clinical remission?
    Subramaniam, K.
    Watthayalage, R.
    Neeman, T.
    Pavli, P.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S353 - S353
  • [30] Immunogenicity, the elephant in the room. Comment on “Drug levels, anti-drug antibodies and clinical efficacy of the anti-TNFα biologics in rheumatic diseases”
    John Pixley
    Clinical Rheumatology, 2013, 32 : 1413 - 1413
12345